General Information of Drug (ID: DM90AG2)

Drug Name
Ularitide Drug Info
Synonyms
Urodilatin; 115966-23-9; Atriopeptin (95-126); Human urodilatin; Urodilatin human; Ularitide [INN]; Urodilatin ularitide; Anf (95-126); Anp (95-126); ANP 95-126; Atrial natriuretic peptide (95-126); CHEMBL2103920; Urodilatin human, > AKOS030213250; DB05034; CDD 95-126; LS-187531; LS-186876; Thr-Ala-Pro-Arg-Atrial Natriuretic Peptide; atrial natriuretic factor prohormone (95-126)
Indication
Disease Entry ICD 11 Status REF
Acute heart failure BD10-BD13 Phase 3 [1]
Heart failure BD10-BD13 Phase 3 [2]
Cross-matching ID
PubChem CID
16132416
CAS Number
CAS 118812-69-4
TTD Drug ID
DM90AG2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nesiritide DMFOIA8 Congestive heart failure BD10 Approved [4]
Ataciguat DM35KDA Neuropathic pain 8E43.0 Phase 2 [5]
Cenderitide DMCT8EY Heart disease BA41-BA42 Phase 2 [6]
PL-3994 DMHUCQS Asthma CA23 Phase 2 [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Atrial natriuretic peptide receptor A (NPR1) TTJME02 ANPRA_HUMAN Modulator [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8446).
3 Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23.
4 The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9.
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 2011 Pipeline of Nile Therapeutics.
7 In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238.